Coming soon to The Easy Pharmacy.
On 11 June 2026, the MHRA approved the first GLP-1 weight-loss tablet for use in the UK, making the UK the first country in Europe to license it. After several years defined by weekly injections, a once-daily oral semaglutide is a real change. Here is what the approval actually covers, what the evidence shows, and how it fits into safe, supported weight management.
What has been approved
The licensed use mirrors the injection: adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related health condition, used alongside a reduced-calorie diet and more physical activity. The dose steps up gradually through 1.5 mg, 4 mg, 9 mg and then a 25 mg maintenance dose, with at least one month at each level. People already on the 2.4 mg weekly injection can move across to the 25 mg tablet.
One point is worth clearing up early, because three oral semaglutide doses now exist and they are easy to confuse. Rybelsus, licensed for type 2 diabetes, goes up to 14 mg. The new Wegovy tablet for weight management is 25 mg. The 50 mg dose some people remember belongs to the earlier OASIS 1 trial and is part of the research, not the approved product.
How it works, and why the morning routine matters
Semaglutide is the same molecule whether it is injected or swallowed. It mimics a natural gut hormone, GLP-1, acting on the appetite centres of the brain to reduce hunger and help you feel full sooner. The difficulty with an oral version is surviving the stomach, which is why the tablet pairs semaglutide with an absorption helper called SNAC and comes with strict rules.
This is the part that makes or breaks results in real life. The tablet is taken whole on an empty stomach, after fasting for at least 8 hours, with only a small sip of plain water, and then no food, drink or other medicine by mouth for 30 minutes. Get this wrong and absorption drops sharply. For someone with a fixed waking time it is straightforward. For someone with variable mornings, or a cluster of other morning medicines, it may be the deciding factor against the tablet.
What the evidence shows
Approval rests mainly on OASIS 4, a phase 3 randomised, double-blind, placebo-controlled trial of 307 adults with overweight or obesity and without diabetes, run over 64 weeks alongside lifestyle support.
The headline depends on how you measure it. On a real-world basis, average weight loss was about 13.6% compared with 2.4% on placebo. With full adherence, it reached 16.6% compared with 2.7%. Around 30% of the semaglutide group lost 20% or more of their body weight, against 3% on placebo. For context, that is broadly in line with the 2.4 mg weekly injection studied in the STEP 1 trial, which is the comparison most people will reach for.
Beyond the scales: the wider health picture
OASIS 4 is as interesting for its effect on health markers as for the weight figures. Alongside weight loss, the trial showed improvements in waist size, HbA1c, fasting glucose, blood fats, blood pressure and an inflammation marker called C-reactive protein.
The blood-sugar shift stands out. Among people who had prediabetes at the start, about 71% returned to normal blood sugar by week 64, compared with about 33% on placebo. Later analyses presented at ObesityWeek 2025 found that people who lost 15% or more of their body weight saw the largest falls in blood pressure and cholesterol, while improvements across blood sugar and heart risk markers appeared regardless of how much weight was lost. These later findings are exploratory and need further study, but the direction is encouraging.
Safety
The safety data are reassuring. Serious adverse events were actually less common on oral semaglutide than on placebo, at about 3.9% against 8.8%. The familiar stomach-related effects were the most common: nausea in roughly 47% of people against 19% on placebo, and vomiting in about 31% against 6%. These were usually mild to moderate, and the rate of stopping treatment because of side effects was around 7%, in line with the injection.
Who it is for
The tablet does not change who is eligible for treatment, but it changes the conversation about how. Its clearest place is the person who wants treatment but does not want injections, and that is not a small group. Around 15 million people in the UK live with obesity, and only a fraction ever access treatment. Removing the needle could genuinely widen reach.
Meeting the BMI threshold is the start of an assessment, not the end of it. Medical history, current medicines, possible interactions and the ability to keep to the fasting routine all matter. This is a medicine that works best with the right person, properly prepared.
When can you get it?
Access will be private at first. The tablet is not yet available on the NHS, and any NHS use will follow the usual NICE assessment, with no confirmed date. Private prescriptions are expected first, in the second half of 2026.
Coming soon to The Easy Pharmacy
We are getting ready to offer oral semaglutide as soon as it launches in the UK. When it arrives, you will get more than a prescription. You will get a proper assessment, clear guidance on the morning routine that makes the tablet work, and real follow-up support to help you keep going.
If you are thinking about weight-loss treatment, our team can talk through your options and check whether it is right for you. To prepare in the meantime, read our Weight Loss Medication Guide and browse our 100 GLP-1 Friendly Recipes.
Frequently asked questions
Is the Wegovy pill available in the UK yet?
It was approved by the MHRA on 11 June 2026 but is not yet on sale. A UK launch is expected in the second half of 2026, with private prescriptions first. It is not yet available on the NHS.
How much weight can you lose on oral semaglutide?
In the OASIS 4 trial, average weight loss was about 13.6% in real-world use and 16.6% with full adherence over 64 weeks, broadly similar to the weekly injection.
How is the Wegovy pill taken?
Once a day, on an empty stomach after fasting for at least 8 hours, with only a small sip of plain water, then nothing to eat, drink or take by mouth for 30 minutes.
Is the pill better than the injection?
Neither is simply better. The pill suits people who prefer to avoid injections and can keep a steady morning routine. The injection suits a once-weekly routine. Both need support and lasting habits to work.
Who can take it?
Adults with a BMI of 30 or above, or 27 to 30 with a weight-related health condition, after a proper assessment of medical history and suitability.
This article is general information, not medical advice. Weight-loss medicines are prescription only and are not suitable for everyone. Always speak to a healthcare professional before starting any treatment, and follow the Summary of Product Characteristics and current guidance once published.
